

Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

<https://marketpublishers.com/r/G0148959CE5AEN.html>

Date: September 2023

Pages: 180

Price: US\$ 5,500.00 (Single User License)

ID: G0148959CE5AEN

Abstracts

Report Scope:

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Includes:

34 data tables and 34 additional tables

A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders

Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028

In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market

Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region

Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology

Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth

Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments

Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders

Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration

Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi

Contents

CHAPTER 1 INTRODUCTION

Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Methodology
Information Sources
Geographic Breakdown

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Market Overview

CHAPTER 3 MARKET OVERVIEW

Introduction
Definitions
Neurons
Central Nervous System
Brain
Spinal Cord
Neurotransmitters
Classification
Progressive Ataxia and Weakness Disorders
Friedreich's Ataxia
Gertsmann-Straussler-Scheinker Disease
Machado-Joseph Disease/SCA3
Amyotrophic Lateral Sclerosis
Hereditary Spastic Paraplegia
Hereditary Neuropathies
Multiple Sclerosis
Diagnostic Tests for Progressive Ataxia and Weakness Disorders
Diagnostic Tests for Multiple Sclerosis
Diagnostic Tests for Amyotrophic Lateral Sclerosis
Diagnostic Tests for Friedreich's Ataxia

Diagnostic Tests for Machado-Joseph Disease
Diagnostic Tests for Hereditary Spastic Paraplegia
Diagnostic Tests for Hereditary Neuropathies

CHAPTER 4 MARKET DYNAMICS

Introduction

Market Drivers

Progressive Ataxia and Weakness: Increasing Prevalence and Awareness

Technological Advancements and Product Launch

Increasing Expenditures for Health Care

Rise in Alcohol and Drug Use

Market Barriers

Barriers to R&D for Progressive Ataxia

Diagnostic Challenges

Opportunities

Advancements in Research and Technology

Impact of COVID-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders

CHAPTER 5 MARKET BREAKDOWN BY TYPE AND TECHNOLOGY

Introduction

Market by Type

Market Overview

Market Revenue

Market by Technology

Market Overview

Market Revenue

Small Molecule

Market Overview

Market Revenue

Monoclonal Antibody

Market Overview

Market Revenue

Others

Biomarkers

Gene Therapy

Stem Cell

Market Overview

Market Revenue

CHAPTER 6 MARKET BREAKDOWN BY DISEASE

Overview

Market Revenue

Market by Progressive Ataxia Diseases Type

Friedreich's Ataxia

Market Revenue

Machado-Joseph disease (MJD)/SCA3

Market Revenue

Gertsmann-Straussler-Scheinker Disease

Market Revenue

Market by Disease Type

Amyotrophic Lateral Sclerosis

Progressive Bulbar Palsy

Hereditary Spastic Paraplegia

Hereditary Neuropathies (HNs)

Multiple Sclerosis (MS)

CHAPTER 7 MARKET BREAKDOWN BY REGION

Introduction

North America

The U.S.

Canada

Europe

The UK

Germany

France

Spain

Italy

Russia

Rest of Europe

Asia-Pacific

Japan

China

India

Australia
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast

CHAPTER 8 MARKET BREAKDOWN BY DISTRIBUTION CHANNEL

Introduction
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

CHAPTER 9 EMERGING TECHNOLOGIES AND DEVELOPMENTS

Introduction
Emerging Technology
Stem Cell Therapy
Gene Therapy
Biomarkers
Nasal Spray for MS
Disease-modifying Therapies
RNA-based Therapies
Conclusion

CHAPTER 10 ESG DEVELOPMENT

Introduction
ESG Investments by Key Players
Consumer Attitudes Towards ESG
Conclusion

CHAPTER 11 PATENT ANALYSIS

Patent Analysis by Year

CHAPTER 12 M&A AND VENTURE FUNDING OUTLOOK AND COMPETITIVE LANDSCAPE

Introduction

Mergers, Acquisitions and Collaborations

Strategic Initiatives

Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs

CHAPTER 13 COMPANY PROFILES

ABBOTT LABORATORIES

ACORDA THERAPEUTICS INC.

AMERICAN REGENT INC.

APOTEX INC.

APOTHECA INC.

ASTELLAS PHARMA INC.

ASTRAZENECA GMBH

BAXTER INTERNATIONAL INC.

BRISTOL-MYERS SQUIBB

EISAI CO. LTD.

ELI LILLY AND COMPANY

GILEAD SCIENCES INC.

GLAXOSMITHKLINE PLC

GLENMARK LIFE SCIENCES

JOHNSON & JOHNSON

MERCK KGAA

NOVARTIS AG

PFIZER INC.

ROCHE HOLDING LTD.

SANOFI

TAKEDA PHARMACEUTICAL CO. LTD.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

CHAPTER 14 APPENDIX: ABBREVIATIONS

List Of Tables

LIST OF TABLES

Summary Table A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028

Summary Table B : Global Market for Progressive Ataxia and Weakness Disorders, Through 2028

Table 1 : Classification, by Primary Dysfunction

Table 2 : Drugs Approved in Europe for Multiple Sclerosis, 2011-2022

Table 3 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028

Table 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028

Table 5 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028

Table 6 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028

Table 7 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028

Table 8 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028

Table 9 : Global Market for Friedreich's Ataxia Drugs, by Region, Through 2028

Table 10 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, Through 2028

Table 11 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, Through 2028

Table 12 : Latest FDA Approvals for Amyotrophic Lateral Sclerosis

Table 13 : Drugs in Clinical Trials for ALS, 2022

Table 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, Through 2028

Table 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, Through 2028

Table 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, Through 2028

Table 17 : Global Market for Hereditary Neuropathies Drugs, by Region, Through 2028

Table 18 : Latest FDA Approvals for Multiple Sclerosis

Table 19 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, Through 2028

Table 20 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by

Region, Through 2028

Table 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028

Table 22 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028

Table 23 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028

Table 24 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, Through 2028

Table 25 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, Through 2028

Table 26 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, Through 2028

Table 27 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, Through 2028

Table 28 : ESG Ranking of Major Players, 2022

Table 29 : ESG Investments, by Key Players, 2022

Table 30 : ESG Trends, Major Players, 2021

Table 31 : ESG Rankings for Major Companies, 2023

Table 32 : CDP Scope Card for Major Players, 2022

Table 33 : Patent Analysis, by Year, Jan. 2020 to March 2023

Table 34 : Major Companies Patents: 2022 to March 2023

Table 35 : M&A: Pharmaceutical Companies

Table 36 : Abbott Laboratories: Annual Revenue, 2022

Table 37 : Abbott Laboratories: News

Table 38 : Abbott Laboratories.: Product Portfolio

Table 39 : Acorda Therapeutics Inc.: News

Table 40 : Acorda Therapeutics Inc.: Product Portfolio

Table 41 : Eli Lilly and Company: Annual Revenue, 2022

Table 42 : Eli Lilly and Company: News

Table 43 : Eli Lilly and Company: Product Portfolio

Table 44 : GlaxoSmithKline PLC: Annual Revenue, 2022

Table 45 : GlaxoSmithKline PLC: News

Table 46 : GlaxoSmithKline PLC: Product Portfolio

Table 47 : Glenmark Life Sciences: Annual Revenue, 2022

Table 48 : Glenmark Life Sciences: Product Portfolio

Table 49 : Novartis AG: Annual Revenue, 2022

Table 50 : Novartis AG: News

Table 51 : Novartis AG: Product Portfolio

Table 52 : Pfizer Inc.: Annual Revenue, 2022
Table 53 : Pfizer Inc.: News
Table 54 : Pfizer Inc.: Product Portfolio
Table 55 : Roche Holding Ltd.: Annual Revenue, 2022
Table 56 : Roche Holding Ltd.: News
Table 57 : Roche Holding Ltd.: Product Portfolio
Table 58 : Sanofi: Annual Revenue, 2022
Table 59 : Sanofi: News
Table 60 : Sanofi: Product Portfolio
Table 61 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2022
Table 62 : Takeda Pharmaceutical Co. Ltd.: News
Table 63 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 64 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2022
Table 65 : Teva Pharmaceutical Industries LTD.: Product Portfolio
Table 66 : Abbreviations

List Of Figures

LIST OF FIGURES

Summary Figure A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Summary Figure B : Global Market for Progressive Ataxia and Weakness Disorders, 2020-2028

Figure 1 : Share of Global Health Expenditure Database, 2022

Figure 2 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2020-2028

Figure 3 : Global Market Shares of Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2022

Figure 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2020-2028

Figure 5 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2022

Figure 6 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028

Figure 7 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028

Figure 8 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028

Figure 9 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2020-2028

Figure 10 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2022

Figure 11 : Global Market for Friedreich's Ataxia Drugs, by Region, 2020-2028

Figure 12 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, 2020-2028

Figure 13 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, 2020-2028

Figure 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, 2020-2028

Figure 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, 2020-2028

Figure 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, 2020-2028

Figure 17 : Global Market for Hereditary Neuropathies Drugs, by Region, 2020-2028

Figure 18 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, 2020-2028

Figure 19 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, 2020-2028

Figure 20 : Global Market Shares of Progressive Ataxia and Weakness Disorders Drugs, by Region, 2022

Figure 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028

Figure 22 : U.S. Market for Progressive Ataxia and Weakness Disorders Drug, 2020-2028

Figure 23 : Canadian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 24 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028

Figure 25 : UK Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 26 : German Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 27 : French Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 28 : Spanish Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 29 : Italian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 30 : Russian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 31 : Rest of European Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 32 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028

Figure 33 : Japanese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 34 : Chinese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 35 : Indian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 36 : Australian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 37 : Rest of Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 38 : Rest of the World Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028

Figure 39 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, 2020-2028

Figure 40 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, 2020-2028

Figure 41 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, 2020-2028

Figure 42 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, 2020-2028

Figure 43 : Benefits of Stem Cell Therapy for the Treatment of Syndrome of Progressive Ataxia and Weakness Disorders

Figure 44 : Environmental, Social and Governance Factors in the Pharmaceutical Industry for Syndromes of Progressive Ataxia and Weakness Disorders Market

Figure 45 : How A Strong ESG Proposition Benefits Pharmaceutical Business

Figure 46 : Share of ESG-Geographical Adoption Level Across All Industries, 2022

Figure 47 : Shares of Patents Registered/Approved, by Country, Jan. 2020 to July 2023

Figure 48 : Global Progressive Ataxia and Weakness Disorders Drugs Market Shares, by Key Manufacturers, 2022

Figure 49 : Abbott Laboratories: Annual Revenue, 2021 and 2022

Figure 50 : Abbott Laboratories: Revenue Shares, by Business Unit, 2022

Figure 51 : Abbott Laboratories.: Revenue Shares, by Region/Country, 2022

Figure 52 : Eli Lilly and Company: Annual Revenue, 2021 and 2022

Figure 53 : Eli Lilly and Company: Revenue Shares, by Business Unit, 2022

Figure 54 : Eli Lilly and Company: Revenue Shares, by Region/Country, 2022

Figure 55 : GlaxoSmithKline PLC: Annual Revenue, 2021 and 2022

Figure 56 : GlaxoSmithKline PLC: Revenue Shares, by Business Unit, 2022

Figure 57 : GlaxoSmithKline PLC: Revenue Shares, by Region/Country, 2022

Figure 58 : Glenmark Life Sciences: Annual Revenue, 2021 and 2022

Figure 59 : Glenmark Life Sciences: Revenue Shares, by Business Unit, 2022

Figure 60 : Novartis AG: Annual Revenue, 2021 and 2022

Figure 61 : Novartis AG: Revenue Shares, by Business Unit, 2022

Figure 62 : Novartis AG: Revenue Shares, by Region, 2022

Figure 63 : Pfizer Inc.: Annual Revenue, 2021 and 2022

Figure 64 : Pfizer Inc.: Revenue Shares, by Business Unit, 2022

Figure 65 : Pfizer Inc.: Revenue Shares, by Region/Country, 2022

Figure 66 : Roche Holding Ltd.: Annual Revenue, 2021 and 2022

Figure 67 : Roche Holding Ltd.: Revenue Shares, by Business Unit, 2022

Figure 68 : Roche Holding Ltd.: Revenue Shares, by Region, 2022

Figure 69 : Sanofi: Annual Revenue, 2021 and 2022

Figure 70 : Sanofi: Revenue Shares, by Business Unit, 2022

Figure 71 : Sanofi: Revenue Shares, by Region/Country, 2022

Figure 72 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2021 and 2022

Figure 73 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, 2022

Figure 74 : Takeda Pharmaceutical Company Limited: Revenue Shares, by
Region/Country, 2022

Figure 75 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2021 and 2022

Figure 76 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Business Unit,
2022

Figure 77 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Region, 2022

I would like to order

Product name: Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Product link: <https://marketpublishers.com/r/G0148959CE5AEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0148959CE5AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

